Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
OBJECTIVE
To investigate the correlation between CD133-positive non-small cell lung cancer (NSCLC) and clinicopathological features and its impact on survival.


METHODS
A search in the Pubmed, Embase and Wanfang databases (up to July 15, 2013) was performed. Only articles in which CD133 antigen was detected in situ localization by immunohistochemical staining were included. This meta-analysis was done using RevMan 5.2 software. Outcomes included overall survival and various clinicopathological features.


RESULTS
A total of 1004 NSCLC patients from 11 studies were included. Meta-analysis showed that CD133 expression patients had a significant worse 5-year overall survival compared to the low expression ones (RR = 3.19, 95% CI: 2.05-4.98, P<0.0001 fixed random). With respect to clinicopathological features, CD133 expression by IHC method was closely correlated with tumor T stage (OR = 0.91, 95% CI: 0.59-1.39, P = 0.67 fixed-effect) and tumor grade (OR = 1.20, 95% CI: 0.80-1.79, P = 0.37 fixed-effect).


CONCLUSIONS
CD133-positive NSCLC patients had worse prognosis, and was associated with common clinicopathological poor prognostic factors.
Cancer Center, Southern Medical University Guangzhou, 510315, China ; Tranditional Chinese Medicine-Integrated Hospital, Southern Medical University Guangzhou, 510315, China ; Department of Oncology, The First Affiliated Hospital, Baotou Medical College Baotou, 014010, China.
Hongying
H
Qu
Rong
R
Li
Zhiyue
Z
Liu
Junyi
J
Zhang
Rongcheng
R
Luo
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D016009:Chi-Square Distribution; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D014411:Neoplastic Stem Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D016017:Odds Ratio; D010455:Peptides / Q000378:metabolism*; D011237:Predictive Value of Tests; D012307:Risk Factors
D000071916:AC133 Antigen; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides
CD133; Non-small cell lung cancer; cancer stem cells; prognosis